Madrigal Pharmaceuticals

Highly Engaged Employees

Madrigal Pharmaceuticals, founded in 2011, is a clinical-stage biopharmaceutical company specializing in the development of therapeutic candidates for cardiovascular, metabolic, and liver diseases. The company focuses on innovative treatments, with its lead candidate, MGL-3196, serving as an orally administered, liver-directed, thyroid hormone receptor (THR)-selective agonist. This compound is currently undergoing clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia, positioning the firm as a key player in the pharmaceutical sector.

Operating with a workforce of 500-1,000 employees across two locations, Madrigal Pharmaceuticals maintains a robust organizational structure to support its research and commercialization efforts. The company leverages its expertise in biopharmaceutical development to advance its pipeline of novel therapies. Meet Madrigal Pharmaceuticals's team to learn about the leadership driving these clinical advancements and the technical expertise supporting their ongoing research initiatives. The firm’s commitment to scientific rigor and patient-centric outcomes remains central to its operational strategy within the competitive healthcare landscape.

Madrigal Pharmaceuticals, traded under the ticker NASDAQ: MDGL, demonstrates significant market presence with annual revenue of $1.1B. The company competes with industry peers such as Exelixis, Alnylam Pharmaceuticals, and Ultragenyx in the development of specialized therapeutic compounds. Explore financial highlights to review detailed metrics regarding their recent funding rounds, including debt and stock issuance activities, and to understand their fiscal performance. By maintaining a focus on high-impact metabolic and liver disease treatments, the company continues to navigate the complexities of the biopharmaceutical market while scaling its operations to meet global healthcare demands.